Company intelligence / Profile preview

BIO-CAT Microbials

Troy, Virginia, United Statesbio-cat.com ↗

Ownership: Private
Employees: ~56
Development stage: Commercial

Overview

BIO-CAT Microbials has published clinical trial results on its proprietary Bacillus subtilis BS50 strain in collaboration with Biofortis Inc., showing promising safety and efficacy data. The company continues to expand its pipeline of well-characterized microbial strains for various applications.

Therapeutic areas: GastroenterologyOther
Modalities: EnzymeProbioticMicrobial therapyLive biotherapeutic product therapy
Industry: Biotech

Drug pipeline

1 asset

bacillus subtilis BS50

Unknown

Partnerships

Biofortis Inc. (Mérieux NutriSciences subsidiary – clinical trials partner)Shin Nihon Enzyme Co.Amano Enzyme Inc. (distribution partnerships)

Beyond the preview

Go deeper on BIO-CAT Microbials.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-CAT Microbials.

Explore the full profile